Stockhead’s Top 10 at 10, published at ~10.30am each trading day, highlights the best (and worst) performing ASX stocks in morning trade using live data.

It’s a short, sharp update to help frame the trading day by showing the biggest movers in percentage terms.

The market opens at 10am (eastern time) and the data is taken at 10:15am, once every ASX stock has started trading.



Stocks highlighted  have made market-moving announcements (click headings to sort).

Wordpress Table Plugin

Gold explorer Sihayo Gold (ASX:SIH) is among the biggest winners this morning after announcing positive results for three more holes in the current drilling program at the company’s Sihayo Starter Project in North Sumatra, Indonesia.

All three holes returned significant gold intercepts. These included:

  • Hole SHDD653 intersected 50.0m @ 7.75g/t Au from 215m, including 22.0m @ 13.14g/t Au from 228m
  • Hole SHDD651 intersected 32.0m @ 4.73g/t Au from 249m, including 18.0m @ 7.55g/t Au from 263m
  • Hole SHDD652 intersected 10.55m @ 3.09g/t Au from 305m, including 4.55m @ 4.98g/t Au from 311m

SIH said 14 holes for 4,736m of diamond drilling have been completed to date with follow-up drilling program testing potential extensions to known deeper high grade gold mineralisation at Sihayo.

Assays are pending for a further six holes (SHDD654-659a) with an additional four holes planned.

The company said results will be used to update the Mineral Resource estimate and be incorporated into a concept study for an independent underground mine at Sihayo



Stocks highlighted  have made market-moving announcements (click headings to sort).

Wordpress Table Plugin


Among the biggest losers today is Race Oncology (ASX:RAC) which has announced Dr Daniel Tillett has stepped down from his roles of executive director and chief scientific officer.

In an announcement RAC said Professor Tim Hammond has been appointed interim CSO, and will work with Dr Tillett and staff to facilitate a smooth transition.

RAC said Tillet’s tenure has been underscored by several major achievements, including the discovery of the cardioprotective properties of Zantrene, a new therapy for melanoma and clear cell renal cell carcinoma, which has opened substantial new market opportunities.